Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer Detection.
Diamand R, Guenzel K, Mjaess G, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Bui AP, Taha F, Oderda M, Gontero P, Rysankova K, Bernal-Gomez A, Mastrorosa A, Roche JB, Fiard G, Abou Zahr R, Ploussard G, Windisch O, Novello Q, Benamran D, Delavar G, Anract J, Barry Delongchamps N, Halinski A, Dariane C, Benijts J, Assenmacher G, Roumeguère T, Peltier A. Diamand R, et al. Among authors: fourcade a. Eur Urol Focus. 2024 Mar 19:S2405-4569(24)00047-6. doi: 10.1016/j.euf.2024.03.003. Online ahead of print. Eur Urol Focus. 2024. PMID: 38508895
Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
Baboudjian M, Diamand R, Uleri A, Beauval JB, Touzani A, Roche JB, Lacetera V, Roumeguère T, Simone G, Benamran D, Fourcade A, Gondran-Tellier B, Fiard G, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: fourcade a. Eur Urol. 2024 Mar 16:S0302-2838(24)00071-X. doi: 10.1016/j.eururo.2024.02.003. Online ahead of print. Eur Urol. 2024. PMID: 38494379
The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy.
Bourgeno HA, Jabbour T, Baudewyns A, Lefebvre Y, Ferriero M, Simone G, Fourcade A, Fournier G, Oderda M, Gontero P, Bernal-Gomez A, Mastrorosa A, Roche JB, Abou Zahr R, Ploussard G, Fiard G, Halinski A, Rysankova K, Dariane C, Delavar G, Anract J, Barry Delongchamps N, Bui AP, Taha F, Windisch O, Benamran D, Assenmacher G, Vlahopoulos L, Guenzel K, Roumeguère T, Peltier A, Diamand R. Bourgeno HA, et al. Among authors: fourcade a. Eur Urol Oncol. 2024 Jan 24:S2588-9311(24)00031-2. doi: 10.1016/j.euo.2024.01.007. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38272745
MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients.
Baboudjian M, Uleri A, Beauval JB, Touzani A, Diamand R, Roche JB, Lacetera V, Lechevallier E, Roumeguère T, Simone G, Benamran D, Fourcade A, Fiard G, Peltier A, Ploussard G. Baboudjian M, et al. Among authors: fourcade a. Prostate Cancer Prostatic Dis. 2023 Jul 14. doi: 10.1038/s41391-023-00693-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37452146
95 results